Friday July 9, 2021
XF-73 Phase 2b data to be presented at ECCMID
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Successful XF-73 nasal gel Phase 2b study data to be presented at 2021 ECCMID Congress Infection prevention expert, Professor Julie Mangino MD […]
Tuesday July 6, 2021
NTCD-M3 RD Agreement with US Dept Veterans Affairs
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma and US Department of Veterans Affairs enter into Cooperative Research and Development Agreement to further research NTCD-M3 for prevention of […]
Friday July 2, 2021